Meeting Report: Risk Assessment of Tamiflu Use Under Pandemic Conditions
Open Access
- 1 November 2008
- journal article
- research article
- Published by Environmental Health Perspectives in Environmental Health Perspectives
- Vol. 116 (11) , 1563-1567
- https://doi.org/10.1289/ehp.11310
Abstract
On 3 October 2007, 40 participants with diverse expertise attended the workshop Tamiflu and the Environment: Implications of Use under Pandemic Conditions to assess the potential human health impact and environmental hazards associated with use of Tamiflu during an influenza pandemic. Based on the identification and risk-ranking of knowledge gaps, the consensus was that oseltamivir ethylester-phosphate (OE-P) and oseltamivir carboxylate (OC) were unlikely to pose an ecotoxicologic hazard to freshwater organisms. OC in river water might hasten the generation of OC-resistance in wildfowl, but this possibility seems less likely than the potential disruption that could be posed by OC and other pharmaceuticals to the operation of sewage treatment plants. The work-group members agreed on the following research priorities: a) available data on the ecotoxicology of OE-P and OC should be published; b) risk should be assessed for OC-contaminated river water generating OC-resistant viruses in wildfowl; c) sewage treatment plant functioning due to microbial inhibition by neuraminidase inhibitors and other antimicrobials used during a pandemic should be investigated; and d) realistic worst-case exposure scenarios should be developed. Additional modeling would be useful to identify localized areas within river catchments that might be prone to high pharmaceutical concentrations in sewage treatment plant effluent. Ongoing seasonal use of Tamiflu in Japan offers opportunities for researchers to assess how much OC enters and persists in the aquatic environment.Keywords
This publication has 22 references indexed in Scilit:
- Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water Treatment: Implications for Development of Resistance by Influenza A VirusPLOS ONE, 2007
- Antiviral Resistance and the Control of Pandemic InfluenzaPLoS Medicine, 2007
- Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanesAntiviral Research, 2006
- Bacterial neuraminidase facilitates mucosal infection by participating in biofilm productionJournal of Clinical Investigation, 2006
- Bacterial neuraminidase facilitates mucosal infection by participating in biofilm productionJournal of Clinical Investigation, 2006
- Antivirals for influenza: Historical perspectives and lessons learnedAntiviral Research, 2006
- Strategies for mitigating an influenza pandemicNature, 2006
- Sensitivity of influenza viruses to zanamivir and oseltamivir: A study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practiceAntiviral Research, 2005
- Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenzaExpert Opinion on Investigational Drugs, 2002
- Treatment of influenza with neuraminidase inhibitors: virological implicationsPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2001